Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: A study of injectable use and toxicity in practice

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1815-1820

  Sturdy, Ann ^a   Goodman, Anna ^b   Joś, Ricardo J ^c   Loyse, Angela ^d   O'Donoghue, Marie ^e   Kon, Onn Min ^e   Dedicoat, Martin J ^f   Harrison, Thomas S ^d   John, Laurence ^b   Lipman, Marc ^c,g   Cooke, Graham S ^a,e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aminoglycosides; Capreomycin; Drug toxicity

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; STREPTOMYCIN;

ADULT; ARTICLE; AUDIOGRAPHY; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OTOTOXICITY; PANCYTOPENIA; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED KINGDOM;

EID: 79960467899     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr221     Document Type: Article

References (25)

1. World Health Organisation. Anti-tuberculosis drug resistance of the world. 2008; WHO/HTM/TB/2008.394. http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf (1 November 2010, date last accessed).
2. O'Riordan P, Schwab U, Logan S et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PLoS One 2008; 3: e3173.
3. Abubakar I, Moore J, Drobniewski F et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 2009; 64: 512-5.
4. World Health Organisation. Guidelines for the programmatic management of drug-resistant tuberculosis. 2008; WHO/HTM/TB/2008.402. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf (1 November 2010, date last accessed).
5. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
6. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
7. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 352-7.
8. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology 2008; 249: 91-6.
9. Peloquin CA, Berning SE, Nitta AT et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538-44.
10. Viljoen DL, Sellars SL, Beighton P. Familial aggregation of streptomycin ototoxicity: autosomal dominant inheritance? J Med Genet 1983; 20: 357-60.
11. Prezant TR, Agapian JV, Bohlman MC et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4: 289-94.
12. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-7.
13. British Society of Audiology. Recommended procedure: pure tone air and bone conduction threshold with and without masking and determination of uncomfortable loudness audiometry levels. 2004; http://www.thebsa.org.uk/docs/RecPro/PTA.pdf (1 April 2011, date last accessed).
14. American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy [guidelines]. 1994; http://www.asha.org/docs/pdf/GL1994-00003.pdf (1 November 2010, date last accessed).
15. British National Formulary. BNF 58. London: BMJ Group and RPS Publishing, 2009.
16. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5.
17. Torun T, Gungor G, Ozmen I et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-7.
18. Heifets L, Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother 1989; 33: 1298-301.
19. Ho YI, Chan CY, Cheng AF. In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. J Antimicrob Chemother 1997; 40: 27-32.
20. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.
21. American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
22. Shin S, Furin J, Alcantara F et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest 2004; 125: 974-80.
23. Bardien S, Human H, Harris T et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet 2009; 10: 2.
24. Human H, Hagen CM, Jong GD et al. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides. Biochem Biophys Res Commun 2010; 393: 751-6.
25. Bardien S, de Jong G, Schaaf HS et al. Aminoglycosideinduced hearing loss: South Africans at risk. S Afr Med J 2009; 99: 440-1.